Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
FLAGYL vs FLAGYL I.V.
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Metronidazole, a nitroimidazole antibiotic, enters bacterial cells and is reduced to cytotoxic intermediates that damage DNA and inhibit nucleic acid synthesis, leading to cell death. It is active against anaerobic bacteria and protozoa.
Metronidazole, a nitroimidazole antibiotic, is reduced by bacterial nitroreductases to form reactive intermediates that disrupt bacterial DNA and inhibit nucleic acid synthesis.
Bacterial vaginosis,Trichomoniasis,Amebiasis,Giardiasis,Anaerobic bacterial infections (intra-abdominal, gynecologic, skin and soft tissue, bone and joint, central nervous system, lower respiratory tract, endocarditis, septicemia),Helicobacter pylori eradication (in combination with other agents),Crohn's disease (off-label),Rosacea (topical, off-label oral use is controversial),Prevention of postoperative infection following colorectal surgery
Intra-abdominal infections (e.g., peritonitis, abscess),Pelvic inflammatory disease,Bacterial vaginosis,Surgical prophylaxis,Anaerobic infections (e.g., Clostridium, Bacteroides),Off-label: Helicobacter pylori eradication, rosacea, Crohn's disease
Metronidazole 500 mg intravenously every 8 hours or 500 mg orally every 8 hours.
500 mg IV every 6 hours. For severe infection, 750 mg IV every 6 hours.
Terminal elimination half-life: 6-8 hours in adults with normal renal function; prolonged to 7-21 hours in hepatic impairment; no significant change in renal impairment; clinically relevant for dosing interval (usually 8-hourly).
8 hours (range 6-12 hours) in adults; prolonged in hepatic impairment (up to 20 hours) and neonates.
Hepatic metabolism via oxidation and glucuronidation; major metabolites include hydroxy metabolite (active) and acid metabolite. CYP450 enzymes involved (CYP2A6, CYP2C9, CYP3A4).
Hepatic metabolism via oxidation and glucuronidation; major metabolites: hydroxy metabolite (active) and acetic acid metabolite; CYP450 involvement primarily CYP2A6 and CYP3A4.
Renal: 60-80% of dose excreted unchanged in urine; biliary/fecal: 6-15% as metabolites and unchanged drug; enterohepatic circulation contributes to prolonged elimination.
Renal (60-80% unchanged), fecal (6-15% as metabolites), biliary (minor).
Less than 20% bound to plasma proteins (primarily albumin).
Less than 20%, primarily bound to albumin.
Volume of distribution: 0.6-0.8 L/kg (approximately 40-60 L in adults), indicating extensive tissue penetration; exceeds total body water, consistent with distribution into all tissues including abscess cavities and CNS.
0.5-0.8 L/kg; indicates extensive tissue distribution, including CNS, bone, and abscesses.
Oral bioavailability: 80-100% (well absorbed); IV bioavailability: 100% (by definition); Topical: Systemic absorption minimal (<2%).
Intravenous: 100%.
No dose adjustment required for mild to moderate renal impairment (GFR >10 m L/min). For severe renal impairment (GFR <10 m L/min), reduce dose to 500 mg every 12 hours.
No dose adjustment for Cr Cl >10 m L/min. For Cr Cl <10 m L/min, extend interval to every 12 hours. For hemodialysis, administer dose post-dialysis.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50% (e.g., 250 mg every 8 hours). Child-Pugh C: reduce dose to 250 mg every 12 hours.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50%. Child-Pugh C: reduce dose by 75%.
15-50 mg/kg/day intravenously or orally divided every 8 hours, depending on infection type and severity. Maximum 4 g/day.
Loading dose: 15 mg/kg IV. Maintenance: 7.5 mg/kg IV every 6 hours. Maximum single dose: 750 mg.
Monitor renal function; same dosing as adults unless severe renal impairment (Cr Cl <10 m L/min) requires dose reduction to 500 mg every 12 hours.
Monitor renal function; adjust dose based on Cr Cl. No specific age-related dose reduction.
Carcinogenicity: Metronidazole has been shown to be carcinogenic in mice and rats. Chromosomal aberrations have been reported in patients with Crohn's disease and other conditions. Use should be reserved for approved indications only.
Carcinogenicity has been observed in chronic animal studies; avoid chronic use unless necessary.
Carcinogenicity risk (see black box warning),Neurologic effects: peripheral neuropathy, seizures, encephalopathy; discontinue if abnormal neurologic signs occur,Hematologic effects: leukopenia, neutropenia; monitor CBC,Hepatic impairment: dosage adjustment recommended,Metronidazole may cause metallic taste, dark urine, and disulfiram-like reaction with alcohol,Prolonged use may result in superinfection (e.g., C. difficile diarrhea),Potential for ethylene glycol toxicity if administered with propylene glycol-containing solutions
Peripheral neuropathy and central nervous system toxicity (e.g., seizures, encephalopathy) with prolonged use; discontinue if neurological symptoms appear; use with caution in hepatic impairment; may cause disulfiram-like reaction with alcohol.
Hypersensitivity to metronidazole or other nitroimidazole derivatives,First trimester of pregnancy (avoid; use during later trimesters only if clearly needed),Breastfeeding (discontinue drug or bottle-feed; excreted in breast milk),History of blood dyscrasias,Concurrent use of disulfiram (psychotic reactions may occur; wait at least 2 weeks after disulfiram),Concurrent use of propylene glycol-containing IV formulations in neonates or patients with renal impairment
Hypersensitivity to metronidazole or nitroimidazoles; first trimester of pregnancy; concomitant use with disulfiram or alcohol.
Avoid alcohol and any products containing ethanol (including certain mouthwashes, cough syrups, and fermented foods) during therapy and for at least 48 hours after last dose. No other food restrictions.
Avoid alcohol and any products containing ethanol (e.g., cough syrups, mouthwash) during therapy and for at least 48 hours after completion. No specific food restrictions.
Flagyl (metronidazole) crosses the placenta. In the first trimester, use is generally avoided due to theoretical risk of teratogenicity, but data from large cohort studies do not show a significant increase in major malformations (risk category B). In the second and third trimesters, no fetal harm has been demonstrated; however, use only if clearly needed. High doses associated with fetal toxicity in animals.
Flagyl I. V. (metronidazole) crosses the placenta. First trimester: Avoid unless essential; no clear evidence of major malformations but risk cannot be excluded (FDA category B). Second and third trimesters: Use only if clearly needed; no documented fetal toxicity at usual doses.
Metronidazole is excreted into breast milk with an M/P ratio of approximately 0.9-1.5. After a single 2 g oral dose, peak milk concentration ~10-20 mcg/m L. The American Academy of Pediatrics considers it compatible with breastfeeding, but because of potential mutagenicity, avoid high doses (e.g., 2 g single dose) for 12-24 hours; resume breastfeeding after 2-3 half-lives. Lower doses (250-500 mg) are considered safe.
Metronidazole is excreted in breast milk; M/P ratio approximately 0.9-1.0. Peak milk concentration 2-4 hours after dose. Breastfeeding not recommended during therapy and for 24 hours after the last dose due to potential carcinogenicity and adverse effects in infant.
No specific dose adjustment for pregnancy. However, due to increased plasma volume and renal clearance, standard doses (e.g., 500 mg IV every 6-8 hours) may require monitoring for efficacy. Oral bioavailability unchanged. Use with caution if hepatic impairment.
No specific dose adjustments required in pregnancy. Pharmacokinetic changes (increased volume of distribution, renal clearance) may slightly reduce serum levels but not necessitate dose modification. Use standard adult dosing with caution in severe hepatic impairment.
Flagyl (metronidazole) is first-line for anaerobic infections and bacterial vaginosis. It can cause a disulfiram-like reaction with alcohol; avoid ethanol during therapy and for 48 hours after last dose. Monitor for peripheral neuropathy with prolonged use. IV formulation is highly irritating; avoid extravasation. Use with caution in hepatic impairment; dose reduction may be needed. Metallic taste is common but benign.
FLAGYL I. V. (metronidazole) is a nitroimidazole antibiotic with potent anaerobic coverage. It is the drug of choice for Clostridioides difficile infection, but oral vancomycin is preferred for severe cases. IV formulation is used when oral route is not feasible. Monitor for peripheral neuropathy with prolonged use. Avoid alcohol during therapy and for 48 hours after last dose due to disulfiram-like reaction. Dose adjustment required in severe hepatic impairment (Child-Pugh C). Metronidazole can prolong QT interval; use caution with other QT-prolonging drugs. It is compatible with most IV solutions but avoid mixing with calcium-containing solutions.
Do not drink alcohol or use products containing alcohol during treatment and for 48 hours after the last dose to avoid severe nausea, vomiting, and flushing.,Take with food to reduce gastrointestinal upset.,Complete the full course even if symptoms improve to prevent resistance.,May cause a metallic taste, which is temporary.,Avoid sexual intercourse or use condoms during treatment for trichomoniasis; partners may need treatment.,Notify doctor if you experience numbness, tingling, or pain in hands/feet.,For vaginal gel, avoid alcohol-containing products (e.g., douches) for 24 hours after use.
Avoid alcohol and alcohol-containing products during treatment and for 48 hours after the last dose to prevent severe nausea, vomiting, headache, and flushing.,Inform your doctor if you experience numbness or tingling in your hands or feet, as this may indicate nerve damage.,Report any new or worsening symptoms, especially if you have liver disease or are on blood thinners like warfarin (metronidazole can increase INR).,Do not take this medication if you are pregnant without consulting your doctor, especially in the first trimester.,Shake the IV bag gently before use; do not use if the solution is cloudy or contains particles.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about FLAGYL vs FLAGYL I.V., answered by our medical review team.
FLAGYL is a Nitroimidazole Antibiotic that works by Metronidazole, a nitroimidazole antibiotic, enters bacterial cells and is reduced to cytotoxic intermediates that damage DNA and inhibit nucleic acid synthesis, leading to cell death. It is active against anaerobic bacteria and protozoa.. FLAGYL I.V. is a Nitroimidazole Antibiotic that works by Metronidazole, a nitroimidazole antibiotic, is reduced by bacterial nitroreductases to form reactive intermediates that disrupt bacterial DNA and inhibit nucleic acid synthesis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between FLAGYL and FLAGYL I.V. depend on the specific clinical indication. These are both Nitroimidazole Antibiotic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of FLAGYL is: Metronidazole 500 mg intravenously every 8 hours or 500 mg orally every 8 hours.. The standard adult dose of FLAGYL I.V. is: 500 mg IV every 6 hours. For severe infection, 750 mg IV every 6 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between FLAGYL and FLAGYL I.V. in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. FLAGYL is classified as Category C. Flagyl (metronidazole) crosses the placenta. In the first trimester, use is generally avoided due to theoretical risk of teratogenicity, but data from large cohort studies do not s. FLAGYL I.V. is classified as Category C. Flagyl I.V. (metronidazole) crosses the placenta. First trimester: Avoid unless essential; no clear evidence of major malformations but risk cannot be excluded (FDA category B). Se. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.